Why it matters: The €7.8 million allocation is a relatively small piece of a much bigger expansion at BII. Earlier this year, the Novo Nordisk Foundation committed up to DKK 5.5 billion (€736 million) to scale the institute through 2035, with a mandate to turn more European research into companies and commercial technologies.
Zoom in: The six recipients are PanTarg, 3Sonic, Inia Biosciences, Yngvi Bio, Proxi Biotech and Sagava. Each previously received a €500,000 convertible loan from BII. The new €1.3 million loans move the companies from BII’s Venture Lab into Venture House, an 18-month follow-on program intended to mature technologies and businesses toward external financing.
- PanTarg, a University of Copenhagen and Rigshospitalet spinout, is developing antibody-based cancer therapies designed to attack both tumor cells and their supporting microenvironment, initially targeting pancreatic cancer.
- 3Sonic, spun out of Rigshospitalet and the Technical University of Denmark (DTU), is developing AI-supported 3D ultrasound to help surgeons assess cancer tissue during an operation.
- Inia Biosciences is developing a wearable ultrasound-based bioelectronic therapy to modulate inflammatory pathways, initially in psoriasis.
- Yngvi Bio, a University of Copenhagen spinout, is developing biological pest-control technologies intended as more targeted alternatives to conventional pesticides.
- Proxi Biotech, spun out of Denmark’s Statens Serum Institut, is developing a vaccine-based immunotherapy against recurrent Clostridioides difficile infections.
- Sagava, a DTU spinout, is developing technology to convert waste biomass into fuels and energy, with maritime decarbonisation as an initial application.
The big picture: BII is increasingly becoming one of the Novo Nordisk Foundation’s main vehicles for tackling Europe’s gap between strong academic science and comparatively weak commercial translation.
- In June, that strategy took a more targeted form with the €60.2 million CardioMetabolic Bridge, a BII-managed network of incubators in the UK, Germany and Italy designed to turn academic cardiometabolic discoveries into drug development projects.
- The six follow-on investments show the other end of the same model: once projects have become companies, BII can continue financing them until they are ready to compete for institutional venture capital.
What to watch: BII’s success will ultimately depend less on how many companies enter its programs than on how many can graduate into independently financed businesses. For these six, attracting external capital is now the next test.
Sign up for our newsletter!
